中国肺癌杂志2018，Vol.21Issue(6)：437-444,8.DOI:10.3779/j.issn.1009-3419.2018.06.03
替吉奥治疗晚期非小细胞肺癌三线及以上患者的疗效分析
Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated with More Than Two Lines of Chemotherapy
摘要
Abstract
Background and objective There is no standard treatment for advanced non-small cell lung cancer (NSCLC) after the failure of two lines of chemotherapy, S-1 as the third generation of fluorouracil derivate with well safety and low toxicity, presented some efficacy in lung cancer treatment. The aim of this study is to explore the efficacy of S-1 for advanced NSCLC patients treated with two or more prior chemotherapy regimens. Methods We performed a retrospective analysis of 105 NSCLC patients treated with S-1 monotherapy or S-1 contained chemotherapy as the third or more line of treatment in our hospital from January 2014 to April 2017. S-1 was administrated orally twice daily for 2 weeks, followed by one week of rest, the dose of drug was determined by body surface area (＜1.25 m2, 80 mg/d; 1.25 m2-1.5 m2, 100 mg/d; ≥1.5 m2, 120 mg/d), platinum or the third-generation chemotherapy drugs could be combinedly used. Clinical response was as-signed every cycle according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Kaplan-Meier analysis was used to estimate progression-free survival (PFS). Results 42 patients received S-1 monotherapy, the other 63 patients re-ceived combined regimens, the median treatment line was 4 (3-11) and the median treatment cycle was 2 (1-14). No complete response (CR) were observed, there were 4 patients with partial response (PR), 34 patients with stable disease (SD) and 67 patients with progressive disease (PD), the objective response rate (ORR) was 3.81%, disease control rate (DCR) was 36.19%.The median PFS was 1.90 months (0.67 months-10.83 months), no difference between monotherapy and combined group (DCR: 28.56% vs 41.27%, P=0.185), the liver metastasis showed poorer PFS (1.40 months vs 1.93 months , P=0.042). Con-clusion S-1 presented some activity in advanced NSCLC treated with more than two lines of treatment. The addition of other drugs cannot improve efficacy. S-1 monotherapy can be used as a choice for heavily-treated patients.关键词
替吉奥/肺肿瘤/化疗/药物耐药Key words
S-1/Lung neoplasms/Chemotherapy/Drug resistance引用本文复制引用
尹一,吴标,黄章洲,庄武,徐振武,黄诚,黄韵坚,张晶..替吉奥治疗晚期非小细胞肺癌三线及以上患者的疗效分析[J].中国肺癌杂志,2018,21(6):437-444,8.基金项目
本研究受福建省医学创新课题(No.2017-CXB-1)和国家临床重点专科建设项目(2013)资助 This study was supported by the grants from Medical Innovation Subject of Fujian (to Biao WU)(No.2017-CXB-1) and National Clinical Key Subject Construction Project (2013). （No.2017-CXB-1）
